Liver News and Research

RSS

Takeda submits NDA for Alogliptin (SYR-322) in the U.S.

Takeda Pharmaceutical Company Limited (Takeda) has announced that Takeda Global Research & Development Center, Inc. submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for alogliptin (development code: SYR-322), a highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes.

7 Jan 2008

Treatment with N-acetylcysteine is associated with better outcomes for children with liver failure

A new retrospective study on the effects of N-acetylcysteine (NAC) on children with acute liver failure not caused by acetaminophen poisoning has found that the treatment was associated with a shorter hospital stay, higher incidence of liver recovery, and better survival after transplantation.

4 Jan 2008

Peptide hormone found in the body prevents obesity and diabetes

A new study finds that a chemical found in the body is capable of promoting weight loss, improving insulin resistance and reversing diabetes in an animal model.

4 Jan 2008

Gene therapy can reduce long-term drinking among rodents

Just as the risk of developing alcoholism is strongly influenced by genetic factors, mutations in gene coding - such as the aldehyde dehydrogenase (ALDH2*2) allele - also appear to protect against the risk.

4 Jan 2008

Shorter HCV treatment shows notable success

Two new randomized controlled trials show that treating Hepatitis C (HCV) with peginterferon and ribavirin for shorter durations can yield success rates similar to those from longer treatment lengths, with cost-savings and lower risk of serious side effects.

3 Jan 2008

MRI techniques evolving towards better assessment of liver fibrosis

MRI imagery is emerging as a non-invasive way to determine the existence and extent of hepatic fibrosis.

3 Jan 2008

Gene variation increases risk of liver tumor in patients with cirrhosis

A particular gene variation appears to significantly increase the risk that individuals with cirrhosis of the liver will go on to develop hepatocellular carcinoma (HCC), a liver tumor that is the third leading cause of cancer death.

2 Jan 2008

Drug effective for hepatitis C patients with low platelets

For patients with hepatitis C, having a low blood platelet count is a frequent complication associated with advanced disease.

2 Jan 2008

Doubt over Gordon Brown's promise to tackle booze problems in Britain

British Prime Minister Gordon Brown appears to be about to do a "U-turn" over Britain's controversial 24-hour drinking laws.

2 Jan 2008

Patient with AIDS finds heart-assit device is an option when transplant is not

Josh Bristow was in the late stages of heart failure when he came to the Emergency Department at Cedars-Sinai Medical Center on Aug. 25, 2007.

28 Dec 2007

Optimal therapy for U.S. hepatitis C patients

As reported recently in the journal Hepatology, WIN-R, a multicenter study of over 5,000 patients with hepatitis C virus (HCV) showed treatment with weight-based REBETOL ribavirin, USP) (RBV) in combination with pegylated interferon (PEG-IFN) alfa-2b achieved significantly higher rates of sustained virologic response (SVR) and lower relapse rates compared to combination therapy using a flat dose of RBV 800 mg/day. Superior response was found particularly in patients with the most difficult-to-treat form of the disease, genotype 1 HCV. Efficacy was consistent across all weight groups.

28 Dec 2007

Fibrosis in the liver stopped and reversed by researchers

University of California, San Diego researchers have proven in animal studies that fibrosis in the liver can be not only stopped, but reversed.

28 Dec 2007

Cell-death receptor links cancer susceptibility and inflammation

For over 10 years, Wafik S. El-Deiry, MD, PhD, Professor of Medicine, Genetics, and Pharmacology at the University of Pennsylvania School of Medicine, has been pursuing a cancer-targeting molecule called TRAIL and its molecular partners.

28 Dec 2007

Researchers prevent muscle weakness caused by myasthenia gravis

Severe muscle weakness caused by myasthenia gravis - a highly debilitating autoimmune disorder - can be prevented or reversed by blocking a key step in the immune response that brings on the disease, researchers at the Saint Louis University School of Medicine have found.

20 Dec 2007

Advanced melanoma - new treatment

University of Illinois at Chicago researchers are participating in a multi-center research trial to evaluate the safety and effectiveness of Allovectin-7, an investigational treatment for advanced melanoma.

20 Dec 2007

20,000 deaths each day from cancer

According to the results of a new report by the American Cancer Society, worldwide in 2007 there were more than 12 million new cancer cases diagnosed.

19 Dec 2007

Short legs linked to an increased risk of liver disease

Short legs are linked to an increased risk of liver disease, suggests a study in the Journal of Epidemiology and Community Health .

18 Dec 2007

New drug that cuts risk of cardiovascular disease shows promise

The first clinical trial of a new kind of drug to cut the risk of cardiovascular disease has been found safe and effective at dropping levels of "bad" low density lipoprotein (LDL) cholesterol by as much as 40 percent.

18 Dec 2007

New understanding on alcohol's role in developing alcoholic chronic pancreatitis

Chronic, excessive alcohol consumption is a major risk factor for developing chronic pancreatitis (pancreatic inflammation).

18 Dec 2007

New mechanical insights into wound healing and scar tissue formation

New research published today in the Journal of Cell Biology illuminates the mechanical factors that play a critical role in the differentiation and function of fibroblasts, connective tissue cells that play a role in wound healing and scar tissue formation.

18 Dec 2007